Refine by
Biomarker Development Articles & Analysis
73 news found
By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of therapeutic candidates into the brain, opening new avenues for preclinical drug development in areas such as Alzheimer's disease, Parkinson's disease, stroke, and epilepsy. ...
With the advancement of biotechnology and biological tools, such as diagnostic technology and animal model development, researchers can further investigate the mechanisms related to depression and thereby develop effective therapies targeting depression. Ace Therapeutics Psychiatry Team is committed to supporting scientists in making groundbreaking scientific ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. ...
“The capabilities that SOPHiA GENETICS provides, from assay development to clinical trial use, help enable this first-in-human precision medicine clinical ...
This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. ...
In fact, Creative Diagnostics is experienced in providing a wide range of immunoassay development services. Based on the unrivaled expertise in developing highly specific diagnostic antibodies for use in sandwich ELISA kits, competitive ELISA kits, and colloidal gold immuno-chromatography strips, Creative Diagnostics has developed diagnostic kits ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. ...
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. ...
This is one of the reasons why the Indian group selected BioMark to develop and commercialize an innovative metabolomic based test for early detection and management of cancer, starting with lung cancer. ...
” Cellworks Precision Drug Development: Pre-clinical Stage Biomarker Development: Cellworks uses cell line data and retrospective patient data to discover novel biomarkers for investigational agents, which can improve drug success rates by prospectively identifying patients who will respond to an agent. ...
Holders of the Warrants may contact the Company at info@biomarkdiagnostics.com, should they have any questions or wish to exercise their Warrants. About BioMark Diagnostics Inc. BioMark is a liquid biopsy company developing a molecular diagnostics technology platform that leverages the power of metabolomics and machine learning algorithms to ...
We at BioMark invest in the right science to have trusted clinical outcomes,” says Rashid Bux, CEO of BioMark. ...
-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). ...
BynVector
The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods. Phages are a group of viruses that invade bacteria, some of which can cause lysis of the host bacteria and some of which can confer additional biological properties to the genetic material of the host bacteria. ...
Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US ...
” says Rashid Bux, CEO of BioMark. About ESMO Founded in 1975, ESMO has European roots with a global reach. ...
By not requiring a wearable device or surgical implant, the solution is designed to seamlessly integrate into a patient’s daily life. We developed the Bodyport Patient Experience — a user-friendly portal combined with convenient tools, resources, biomarker-guided coaching, and more — to empower patients to track their health, stay on treatment, ...
The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools in close collaboration with regulatory agencies to enable easier and faster regulatory ...